[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda Ospedaliera di Padova\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":277},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,71,112,141,166,189,218,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100623099","phase-2-zanubritnib-and-anti-mag-neuropathy-100623099",false,"NCT07392229","Zanubritnib and Anti-MAG Neuropathy","Zanubrutinib, a Second Generation BTK Inhibitor, in Anti-MAG Antibody Neuropathy: a Phase II Italian Multicenter Clinical Trial (MAZINGA)","MAZINGA","Inclusion Criteria (MAIN):\n\n* age ≥18 years;\n* diagnosis of anti-MAG antibody polyneuropathy;\n* neurophysiological (ENG\u002FEMG) evidence of a demyelinating polyneuropathy with evidence of disproportionately prolonged distal motor latency in one or more nerves -excluding the median nerve if related to carpal tunnel syndrome\n* IgM monoclonal protein underlying MGUS (based on the WHO definition of clonal lympho- plasmocytes \\\u003C10%), Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified;\n* presence of anti MAG antibodies (titer ≥ 7.000 BTU);\n* neurophysiological (ENG\u002FEMG) evidence of demyelinating polyneuropathy.\n\nExclusion Criteria (MAIN):\n\n* Previous treatment with BTK inhibitors\n* Aggressive non-Hodgkin lymphoma or IgM multiple myeloma\n* Evidence of moderate or severe motor nerve axonal damage, defined when occurring diffuse polyneuropathic denervation or a recruitment pattern lower than intermediate in ≥50% of muscles examined, and\u002For INCAT at lower limbs ≥4.\n* ECOG \\>3\n* Use of strong CYP3A inducers within 14 days prior to the first dose of zanubrutinib","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) antibody-associated demyelinating polyneuropathy. Anti-MAG neuropathy is a rare immune-mediated disorder frequently associated with IgM monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, and other indolent B-cell lymphoproliferative disorders.\n\nThe primary objective of the study is to determine whether 12 months of treatment with zanubrutinib leads to a clinically meaningful neurological improvement, defined as an improvement of at least one point in at least two validated neurological scales. These include reductions in the Overall Neuropathy Limitations Scale (ONLS), INCAT Disability Score, and INCAT Sensory Sum Score (ISS), along with increases in the Medical Research Council (MRC) sum score and the I-RODS functional score.\n\nSecondary objectives include the evaluation of neurophysiological improvement assessed by nerve conduction studies (ENG\u002FEMG), particularly changes in distal motor latency, terminal latency index, and sensory action potential amplitude at 12, 24, and 48 months. Additional secondary endpoints assess hematological efficacy through overall response rate (complete response, very good partial response, or partial response), event-free survival, time to neurological progression, and overall survival. The safety profile of zanubrutinib will be characterized by the incidence, type, and severity of adverse events, serious adverse events, and events of special interest.\n\nEligible participants are adults (≥18 years) with a confirmed diagnosis of anti-MAG IgM-associated demyelinating polyneuropathy, evidence of a relevant IgM monoclonal gammopathy, elevated anti-MAG antibody titers, and measurable neurological disability. Both treatment-naïve and relapsed\u002Frefractory patients are eligible. Key exclusion criteria include prior treatment with BTK inhibitors, aggressive lymphomas, significant axonal damage, uncontrolled comorbidities, active infections, pregnancy, or conditions that could interfere with study participation or safety evaluation.\n\nThe planned sample size is approximately 50 patients recruited from nine Italian centers. Statistical analyses will compare neurological outcomes with historical controls, estimate survival endpoints using Kaplan-Meier methods, and explore associations between clinical outcomes and molecular features. This study aims to provide robust prospective evidence on the role of BTK inhibition in anti-MAG neuropathy and to inform future therapeutic strategies for this rare and disabling condition.",[27],"Anti-MAG IgM-associated Demyelinating Polyneuropathy","RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2026-03-24",{"date":36,"type":21},"2031-03",{"name":38,"class":39},"Azienda Ospedaliera di Padova","OTHER",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100611521","surgery-for-locally-unresectable-pancreatic-cancer-100611521","NCT07241663","Surgery for Locally Unresectable Pancreatic Cancer","Conversion Surgery for Locally Unresectable Pancreatic Cancer - International Multi-center Observational Trial (ROBIN= suRgery for lOcally unresectaBle pancreatIc Cancer)","ROBIN","Inclusion Criteria:\n\n* Patients older than 18 years\n* Patients able to give informed consent\n* Histologically confirmed pancreatic adenocarcinoma\n* LAPC stage according to NCCN10 at diagnosis (Figure 1)\n* Received at least 4 months of induction chemotherapy\n* RECIST 1.1 stable disease (SD) or partial response (PR) after induction therapy\n* Patient considered eligible for radical resection by local MDT\n\nExclusion Criteria:\n\n* Informed consent withdrawal\n* Presence of tumor characteristics precluding surgery\n* Presence of patient significant comorbidities precluding surgery\n* Unavailable pre-induction therapy abdominal imaging\n* Pathological confirmation of any tumor different from PDAC",{"count":50,"type":21},150,"OBSERVATIONAL","Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option. This study aims to understand if surgery after such treatments can improve survival and quality of life in selected patients treated at expert centers.",[54],"Locally Advanced Pancreatic Adenocarcinoma",[56,57,58,59,60,61],"Pancreatic cancer","Coversion Surgery Pancreatic Cancer","Quality of Life","Locally advanced PDAC","Unresectable Pancreatic Cancer","Neoadjuvant therapy for pancreatic cancer","2025-11-21",{"date":64,"type":32},"2025-11-26",{"date":66,"type":32},"2025-01-01",{"date":68,"type":21},"2028-12-31",{"name":38,"class":39},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":82,"conditions":83,"keywords":98,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":70},"100598488","an-international-study-on-pediatric-patients-with-rare-tumors-100598488","NCT07072143","An International Study on Pediatric Patients With Rare Tumors.","The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.","PARTNER","Inclusion Criteria:\n\n* Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and\u002For treated in a participating country\u002Fcenter.\n* Written informed consent from the patient and\u002For the parent\u002Flegal guardian\n\nExclusion Criteria:\n\n* Absence of Written informed consent from the patient and\u002For the parent\u002Flegal guardian","0 Years",{"count":81,"type":21},6250,"The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.",[84,85,86,87,88,89,90,91,92,93,94,95,96,97],"Paraganglioma\u002F Phaeochromocytoma","Melanoma and Other Malignant Neoplasms of Skin","Gastrointestinal Stromal Tumor (GIST)","Adrenocortical Tumor","Pancreatic Tumors","Esthesioneuroblastoma, Olfactory","Mesothelioma","Nasopharyngeal Carcinoma (NPC)","NUT Carcinoma","Pleuropulmonary Blastoma","Salivary Gland Tumors","Thymic Tumors","Thyroid Carcinoma","Appendiceal Cancers",[99,100,101,102,103],"children","rare tumors","very rare tumors","adolescents","PARTNER Study","2025-07-16",{"date":106,"type":32},"2025-07-18",{"date":108,"type":32},"2025-01-25",{"date":110,"type":21},"2049-06-06",{"name":38,"class":39},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":17,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100597321","surveillance-discontinuation-in-5-year-stable-trivial-branch-duct-intraductal-papillary-mucinous-neoplasms-100597321","NCT07056972","Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms","Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms (TRIVIAL): International Prospective Single Arm Multicenter Trial","TRIVIAL","Inclusion Criteria:\n\n* Oral and written informed consent;\n* Age ≥70 years;\n* BD IPMN with ≥1 dilated branch duct(s) communicating with a nondilated main pancreatic duct (≤5 millimeter) as seen on Magnetic Resonance Cholangio-Pancreatography (MRCP), performed within the last 3 months prior to inclusion;\n* At least 5 years of follow up prior to inclusion;\n* Absence of relative and absolute indications for surgery at diagnosis and inclusion according to European guidelines;\n* Absence of worrisome features and\u002For high risk stigmata at diagnosis and inclusion according to IAP guidelines;\n* Cyst size ≤30 millimeters.\n\nExclusion Criteria:\n\n* Personal or familial history of pancreatic cancer;\n* History of pancreatic surgery;\n* Withdrawal of informed consent.",true,"70 Years",{"count":123,"type":21},394,"BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the general population. In these patients, d iscontinuation of surveillance seems feasible . However, prospective studies to confirm the safety of this approach are lacking.\n\nAIM: To assess whether current surveillance policies for stable, trivial BD IPMN can be discontinued safely after 5 years of follow up .\n\nMETHODS: TRIVIAL is an international prospective multicenter single arm trial exploring discontinuation of surveillance in patients with at least 5 years stable trivial BD IPMN. The trial will include 394 adult patients at least 70 years of age with BD IPMN ≤ 30 millimeter without worrisome features or high risk stigmata during 5 years. The primary endpoint is rate of PC and futile surgery (i.e., surgery for low grade dysplasia IPMN or other non malignant pathology) during 5 year follow up. The predefined target is a rate of 1% and below 3%.\n\nSTRENGTHS: The burden for patients to participate in this trial is negligible. P atients will only be asked to answer self reported digital surveys once per year during five years . The potential benefits for patients are twofold: the psychological impact of potentially unnecessary surveillance will be spared to patients , whereas the socio economic burden of repeated imaging will be avoided. Moreover, the study will provide data contributing to the development of new, evidence based surveillance strateg ies At the end of follow up patients undergo MRCP to assess disease course (i.e., development of worrisome features, high risk stigmata, PC).\n\nLIMITATIONS: The most prominent risk of IPMN is the development of pancreatic cancer However this risk will not be omitted fully by the TRIVIAL trial eligibility criteria as participants still have the same risk as the general population. This requires adequate counselling",[126,127],"IPMN","Pancreatic Cancer",[129,130,131],"ipmn","pancreatic cancer","discontinuation of surveillance","NOT_YET_RECRUITING","2025-07-06",{"date":135,"type":32},"2025-07-09",{"date":137,"type":21},"2025-07-01",{"date":139,"type":21},"2031-09-01",{"name":38,"class":39},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":148,"minAge":149,"maxAge":18,"enrollmentInfo":150,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":70},"100513746","validation-of-a-processed-eeg-device-for-monitoring-sedation-in-picu-100513746","NCT05969483","Validation of a Processed EEG Device for Monitoring Sedation in PICU","Validation of a Processed EEG Device (pEEG, Masimo Sedline®) as a Monitoring Tool for the Analgosedation Level in Mechanically Ventilated Critically Ill Children","Inclusion Criteria:\n\n\\- sedated and ventilated patients admitted in PICU\n\nExclusion Criteria:\n\n* skin lesions\n* significant traumatic lesions in the area where the Masimo Sedline® sensor need to be applied.","FEMALE","1 Day",{"count":50,"type":21},"The goal of this prospective observational study is to validate pEEG as a monitoring tool for the analgosedation level in mechanically-ventilated critically ill children, receiving or not-receiving NMBAs. The main question aims to answer is to measure the strength of agreement between pEEG score and Comfort Behavioural Scale (CBS) (goal standard).\n\nParticipants will be monitored with pEEG and CBS evaluated during PICU admission. paralysis holiday) by a specialized PICU nurse and by a critical-care expert physician, blinded to each other.",[153],"Sedation Complication",[155,156,157],"sedation","pediatric intensive care","monitoring","2025-01-27",{"date":160,"type":32},"2025-01-28",{"date":162,"type":32},"2022-10-01",{"date":164,"type":21},"2025-03",{"name":38,"class":39},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":174,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100465387","non-invasive-measurement-with-trans-cranial-doppler-versus-invasive-measurement-in-pediatric-age-100465387","NCT05340062","Non Invasive Measurement With Trans Cranial Doppler Versus Invasive Measurement in Pediatric Age","The Accuracy of Intracranial Pressure Non Invasive Measurement With Trans Cranial Doppler Versus Invasive Measurement in Pediatric Age","nICPped","Inclusion Criteria:\n\n* invasive ICP placement\n\nExclusion Criteria:\n\n* cranial base fracture\n* absent informed consent",{"count":175,"type":21},46,"An increase of intracranial pressure (ICP) is an important cause of secondary brain damage. The gold standard for measuring ICP is represented by invasive positioning of intracranial ICP devices.\n\nThe most used non-invasive methods (nICP) are obtained through bed-side ultrasound, routinely used in the management of children in Pediatric Intensive Care: arterial Trancranial Doppler (TCD) and ultrasound measurement of the diameter of the optic nerve sheath (ONSD ).\n\nIn this study it is proposed to compare the measurement of nICP obtained by TCD and ONSD versus the measurement obtained by the invasive monitoring (iICP) already present.",[178],"Intracranial Hypertension",[180,99,181],"intracranial hypertension","cerebral perfusion",{"date":160,"type":32},{"date":184,"type":32},"2022-07-01",{"date":186,"type":21},"2025-12-31",{"name":38,"class":39},6,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":198,"studyType":51,"phases":4,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":70},"100571486","robotically-assisted-surgery-for-perihilar-cholangiocarcinoma-a-prospective-study-100571486","NCT06720883","Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study","ROBOCHOL","Inclusion Criteria:\n\n* Age≥18 years\n* Histologically proven pCCA or highly presumed bile duct malignancy with difficulties to obtain histological evidence with negative Immunoglobulin G4 (IgG4 sample)\n* Preoperative staging work up performed by abdomen enhanced CT scan.\n* The subject understands the nature of this trial and is willing to comply.\n* Ability to provide written informed consent.\n* Patients treated with curative intent in accordance to international guidelines\n\nExclusion Criteria:\n\n* Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node metastases, involvement of other organs.\n* Previous radiotherapy\n* Vascular encasement\n* Patients with high operative risk as defined by the American Society of Anesthesiologists (ASA) score\\>4.\n* Synchronous malignancy in other organs.\n* Palliative surgery",{"count":197,"type":21},32,"5 Years","Cholangiocarcinoma (CCA) represents the most common biliary tract malignancy, and the second most common primary hepatic malignancy, accounting for 15% to 20% of primary liver tumours.\n\nPerihilar cholangiocarcinoma (pCCA) involves the biliary confluence with or without involvement of the right and left hepatic ducts. Complete resection with negative histologic margins is the only chance of cure and the most robust predictor of long-term survival for patients affected by any type of locally advanced CCA. However, the proximity of perihilar tumors to vital structures makes curative excision technically difficult.\n\nMinimally invasive approaches are progressively spreading in liver surgery units worldwide. Significant advantages of minimally invasive liver resections, if compared to open one, have been diffusely shown, such as shorter hospital stay and possibility of complex reconstructive procedures similar to those performed in open surgery. Robot-assisted liver surgery represents a natural consequence of such a minimally invasive evolution.\n\nThis is a monocentric, single arm, observational, prospective study that aims at analyzing the outcomes of robotic major liver resection and biliary recontruction for perihilar cholangiocarcinoma.\n\nAmong study outcomes, the primary outcome is evaluation of morbidity; secondary outcomes includes conversion rate, margin status, biliary fistula, liver failure, disease specific survival, overall Survival\n\nData related to patient condition (laboratory tests, etc.), surgery performed, and post-surgical course will be collected.\n\nThe protocol for this study has been developed in accordance with the European Union Good Clinical Practice guidelines and the Declaration of Helsinki, and it has been approved by the Territorial Ethics Committee of the East-Central Veneto Area (CETAEV).",[201,202],"Cholangiocarcinoma Cancer","Perihilar Cholangiocarcinoma",[204,205,206,207,208,209],"cholangiocarcinoma","robot","robotic","perihilar","cca","phc","2024-12-05",{"date":212,"type":32},"2024-12-06",{"date":214,"type":32},"2024-06-07",{"date":216,"type":21},"2031-07-07",{"name":38,"class":39},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":70},"100569152","phase-2-conversion-surgery-vs-palliative-care-in-pancreatic-cancer-oligometastatic-to-the-liver-100569152","NCT06690528","Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver","Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver (SONAR: Surgery in Oligometastatic PaNcreatic CAnceR) a Randomized Controlled Trial","SONAR","Inclusion Criteria:\n\n* Adult patients aged ≥18 years and ≤75 years (at diagnosis).\n* Cytologically or histologically confirmed pancreatic adenocarcinoma either resectable or borderline resectable (at diagnosis) according to National Comprehensive Cancer Network (NCCN)4 (see section 5).\n* Synchronous oligometastatic disease (at diagnosis), defined as a limited number of radiologically documented liver metastases (up to 3 lesions).\n* No evidence of extrahepatic metastases (at diagnosis.)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (at enrollment)\n* Partial response or stable disease after completion of first-line chemotherapy, as determined by RECIST 1.1 criteria21 (modified to exclude any % of increase in the sum of diameters of target lesions) (at enrollment).\n* Decreasing or stable (defined as ≤20% increase) serum CA19-9 level after chemotherapy (at enrollment).\n* Liver metastases considered resectable (see section 5) or alternatively treatable by needle ablation\u002Fmicrowave once no larger than 20 mm (at enrollment).\n\nExclusion Criteria:\n\n* Locally advanced pancreatic cancer according to NCCN4.\n* Unresectable liver disease (according to multidisciplinary discussion).\n* Involvement of other organs.\n* Presence of significant comorbidities precluding surgery.\n* Pregnancy.\n* Contraindications to surgical resection.\n* Prior surgical resection of the primary tumor or liver metastases.\n* Evidence of extrahepatic metastases.\n* Inability to provide informed consent or participate in follow-up assessments.\n* Disease progression as determined by RECIST 1.1 criteria21 (modified to include any % of increase in the sum of diameters of target lesions) after chemotherapy.\n* Serum CA19-9 level increase \\>20% after chemotherapy.\n\nNote: Additional specific exclusion criteria may be defined at each participating center based on their institutional guidelines and patient population.","75 Years",{"count":228,"type":21},56,[24],"This study investigates the impact of surgical resection compared to palliative care in patients with oligometastatic pancreatic cancer limited to the liver. Specifically, it examines whether surgery after stable disease or response to chemotherapy can improve survival and quality of life. The international, multicenter randomized trial will recruit 56 patients, assigning them to either surgical resection (including tumor and liver metastases) or ongoing palliative care with chemotherapy. Stratification by performance status, tumor markers, and tumor location will ensure balanced study groups. Outcome assessments, conducted over a minimum two-year follow-up, include clinical evaluations, imaging, and quality-of-life metric",[232],"Pancreatic Cancer Metastatic",[234,235,57,236,237,238,239],"Pancreatic Cancer Metastatic to Liver","Pancreatic Cancer Oligometastatic to Liver","NEoadiuvant Therapy for Oligometastatic Pancreatic Cancer","Resectable Pancreatic Cancer","Resectable Liver Metastasis in Pancreatic Cancer","Combined Surgery for Metastatic Pancreatic Cancer","2024-11-13",{"date":242,"type":32},"2024-11-15",{"date":244,"type":32},"2024-11-06",{"date":246,"type":21},"2028-11",{"name":38,"class":39},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":148,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":70},"100505542","ultra-lap-trial-laparoscopic-debulking-surgery-lds-in-advanced-ovarian-cancer-100505542","NCT05862740","ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer","ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer: a Feasibility Prospective Study","ULTRA-LAP","Inclusion Criteria:\n\n* Patients with advanced epithelial ovarian cancer (II-IV Stage FIGO) candidates to PDS (primary debulking surgery) or IDS (interval debulking surgery: neoadjuvant chemotherapy followed by IDS).\n* Participant is willing and able to give informed consent for participation in the study.\n* Female aged 18 years or above.\n* Primary diagnosis of advanced epithelial ovarian cancer (tubal and peritoneal cancer included).\n\nExclusion Criteria:\n\n* Comorbidities non-allowing for radical surgery\n* Poor Performance Status (Karnofsky Index \\\u003C 70)\n* Concomitant or past history of malignancy, regardless of treatment status\n* Recent or past story of pancreatitis or hepatitis\n* Recent or past story of pleural effusion or lung injuries or respiratory failure\n* Cardiac major pathologies",{"count":257,"type":21},62,[259],"NA","ULTRA-LAP is a prospective study is to investigate the safety, efficacy and feasibility of laparoscopic debulking surgery (LDS) for the treatment of patients with advanced ovarian cancer.\n\nThe outcomes to measure are:\n\n* Safety: the rate of patients experiencing intra- and post-operative early and late morbidities (within the hospitalization and up to 60 days from surgery)\n* Efficacy: the rate of patients in which the surgical target set pre-operatively (complete resection) is achieved by laparoscopy.\n* Feasibility: the rate of patients who have their procedure completed by laparoscopy\n\nPatients will undergo laparoscopic debulking surgery (LDS) if the surgical target can be met. If it cannot be achieved by laparoscopy the surgeon will convert to laparotomy.",[262],"Ovarian Cancer",[264,265,266,267,268],"Ovarian cancer","Advanced ovarian cancer","Debulking surgery","Multivisceral surgery","Laparoscopic debulking surgery","2023-05-08",{"date":271,"type":32},"2023-05-17",{"date":273,"type":32},"2022-01-02",{"date":275,"type":21},"2027-12-31",{"name":38,"class":39},""]